128 related articles for article (PubMed ID: 1515582)
1. Dopamine fiber detection by [11C]-CFT and PET in a primate model of parkinsonism.
Hantraye P; Brownell AL; Elmaleh D; Spealman RD; Wüllner U; Brownell GL; Madras BK; Isacson O
Neuroreport; 1992 Mar; 3(3):265-8. PubMed ID: 1515582
[TBL] [Abstract][Full Text] [Related]
2. Dopamine terminal loss and onset of motor symptoms in MPTP-treated monkeys: a positron emission tomography study with 11C-CFT.
Wüllner U; Pakzaban P; Brownell AL; Hantraye P; Burns L; Shoup T; Elmaleh D; Petto AJ; Spealman RD; Brownell GL
Exp Neurol; 1994 Apr; 126(2):305-9. PubMed ID: 7925829
[TBL] [Abstract][Full Text] [Related]
3. Cocaine congeners as PET imaging probes for dopamine terminals.
Brownell AL; Elmaleh DR; Meltzer PC; Shoup TM; Brownell GL; Fischman AJ; Madras BK
J Nucl Med; 1996 Jul; 37(7):1186-92. PubMed ID: 8965196
[TBL] [Abstract][Full Text] [Related]
4. SPECT imaging of dopamine transporter sites in normal and MPTP-Treated rhesus monkeys.
Fischman AJ; Babich JW; Elmaleh DR; Barrow SA; Meltzer P; Hanson RN; Madras BK
J Nucl Med; 1997 Jan; 38(1):144-50. PubMed ID: 8998169
[TBL] [Abstract][Full Text] [Related]
5. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment.
Elsworth JD; Taylor JR; Sladek JR; Collier TJ; Redmond DE; Roth RH
Neuroscience; 2000; 95(2):399-408. PubMed ID: 10658619
[TBL] [Abstract][Full Text] [Related]
6. Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model.
Brownell AL; Canales K; Chen YI; Jenkins BG; Owen C; Livni E; Yu M; Cicchetti F; Sanchez-Pernaute R; Isacson O
Neuroimage; 2003 Oct; 20(2):1064-75. PubMed ID: 14568476
[TBL] [Abstract][Full Text] [Related]
7. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey.
Pifl C; Schingnitz G; Hornykiewicz O
Neuroscience; 1991; 44(3):591-605. PubMed ID: 1754053
[TBL] [Abstract][Full Text] [Related]
8. MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates.
Zuddas A; Oberto G; Vaglini F; Fascetti F; Fornai F; Corsini GU
J Neurochem; 1992 Aug; 59(2):733-9. PubMed ID: 1629743
[TBL] [Abstract][Full Text] [Related]
9. Tremor is associated with PET measures of nigrostriatal dopamine function in MPTP-lesioned monkeys.
Eberling JL; Pivirotto P; Bringas J; Bankiewicz KS
Exp Neurol; 2000 Oct; 165(2):342-6. PubMed ID: 10993693
[TBL] [Abstract][Full Text] [Related]
10. Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease.
Andringa G; Drukarch B; Bol JG; de Bruin K; Sorman K; Habraken JB; Booij J
Neuroimage; 2005 Jul; 26(4):1150-8. PubMed ID: 15908232
[TBL] [Abstract][Full Text] [Related]
11. 6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys.
Doudet DJ; Chan GL; Holden JE; McGeer EG; Aigner TA; Wyatt RJ; Ruth TJ
Synapse; 1998 Jul; 29(3):225-32. PubMed ID: 9635892
[TBL] [Abstract][Full Text] [Related]
12. Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys.
Alexander GM; Schwartzman RJ; Brainard L; Gordon SW; Grothusen JR
Brain Res; 1992 Aug; 588(2):261-9. PubMed ID: 1356591
[TBL] [Abstract][Full Text] [Related]
13. Peripheral nerve-dopamine neuron co-grafts in MPTP-treated monkeys: augmentation of tyrosine hydroxylase-positive fiber staining and dopamine content in host systems.
Collier TJ; Elsworth JD; Taylor JR; Sladek JR; Roth RH; Redmond DE
Neuroscience; 1994 Aug; 61(4):875-89. PubMed ID: 7838385
[TBL] [Abstract][Full Text] [Related]
14. Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment.
Schneider JS; Pope A; Simpson K; Taggart J; Smith MG; DiStefano L
Science; 1992 May; 256(5058):843-6. PubMed ID: 1350379
[TBL] [Abstract][Full Text] [Related]
15. A novel MPTP primate model of Parkinson's disease: neurochemical and clinical changes.
Eberling JL; Jagust WJ; Taylor S; Bringas J; Pivirotto P; VanBrocklin HF; Bankiewicz KS
Brain Res; 1998 Sep; 805(1-2):259-62. PubMed ID: 9733979
[TBL] [Abstract][Full Text] [Related]
16. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.
Jenner P; Rupniak NM; Rose S; Kelly E; Kilpatrick G; Lees A; Marsden CD
Neurosci Lett; 1984 Sep; 50(1-3):85-90. PubMed ID: 6436758
[TBL] [Abstract][Full Text] [Related]
17. Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates.
Albanese A; Granata R; Gregori B; Piccardi MP; Colosimo C; Tonali P
Neuroscience; 1993 Aug; 55(3):823-32. PubMed ID: 8105418
[TBL] [Abstract][Full Text] [Related]
18. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
Falardeau P; Bouchard S; Bédard PJ; Boucher R; Di Paolo T
Eur J Pharmacol; 1988 May; 150(1-2):59-66. PubMed ID: 3261249
[TBL] [Abstract][Full Text] [Related]
19. Dopamine imaging markers and predictive mathematical models for progressive degeneration in Parkinson's disease.
Brownell AL; Jenkins BG; Isacson O
Biomed Pharmacother; 1999 Apr; 53(3):131-40. PubMed ID: 10349501
[TBL] [Abstract][Full Text] [Related]
20. Dopamine transporter loss and clinical changes in MPTP-lesioned primates.
Eberling JL; Bankiewicz KS; Pivirotto P; Bringas J; Chen K; Nowotnik DP; Steiner JP; Budinger TF; Jagust WJ
Brain Res; 1999 Jun; 832(1-2):184-7. PubMed ID: 10375668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
